CLINICAL TRIAL: PALIFERMIN (FHUKGF) FOR THE TREATMENT OF INADEQUATE CD4 & LUMPHO

临床试验：PALIFERMIN (FHUKGF) 用于治疗 CD4 不足

• 批准号: 7716887
• 负责人: Charles Michael van der Horst
• 金额: $ 1.34万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-02 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716887
• 关键词: Age; CD4 Lymphocyte Count; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Growth; Growth Factor; Institution; Intravenous Bolus; Liquid substance; Methods; Participant; Placebos; Powder dose form; Procedures; Purpose; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Week; Woman; cell growth; day; keratinocyte growth factor; men; pill

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: This study will look at whether one type of growth factor, palifermin (rHuKGF), a substance that promotes growth and especially cell growth, can safely increase your CD4+ cell count. This will be done by comparing three different doses of palifermin to placebo (an inactive pill, liquid, or powder that has no treatment value). Participants: HIV-1-infected Men and women age greater than or equal to 18 years. Procedures (methods): To maintain study product blinding, each subject will receive three IV bolus doses of palifermin or palifermin placebo on each of 3 consecutive days: day 1 (Entry), day 2, and day 3. Subjects will be followed on study for a total of 24 weeks. Subjects must receive potent ART for the duration of the trial. ART will not be provided through A5212.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 目的：这项研究将研究一种生长因子（rhukgf）（一种促进生长，尤其是细胞生长的物质）是否可以安全地增加您的CD4+细胞计数。这将通过将三种不同剂量的califermin与安慰剂（一种没有治疗价值的无活性药物，液体或粉末）进行比较来完成。 参与者：HIV-1感染的男女年龄大于或等于18岁。 程序（方法）：为了维持研究产品的盲目，每个受试者连续3天都将接受三个IV剂量的环囊甘油或环晶安慰剂：第1天（条目），第2天和第3天。在试验期间，受试者必须获得有效的艺术。艺术将不会通过A5212提供。